Wall Street brokerages expect VBI Vaccines Inc (NASDAQ:VBIV) to post $2.13 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for VBI Vaccines’ earnings, with the highest sales estimate coming in at $4.00 million and the lowest estimate coming in at $270,000.00. The firm is expected to issue its next quarterly earnings report on Friday, February 8th.
On average, analysts expect that VBI Vaccines will report full-year sales of $2.97 million for the current fiscal year, with estimates ranging from $940,000.00 to $5.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $2.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow VBI Vaccines.
Get VBI Vaccines alerts:
VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). VBI Vaccines had a negative net margin of 6,345.29% and a negative return on equity of 56.88%. The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.24 million.
Several research analysts recently commented on the company. Zacks Investment Research cut VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Tuesday, January 22nd. ValuEngine raised VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Oppenheimer assumed coverage on VBI Vaccines in a research report on Wednesday, January 16th. They issued an “outperform” rating and a $9.00 target price for the company. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. VBI Vaccines has a consensus rating of “Buy” and a consensus target price of $10.50.
Shares of VBIV traded down $0.07 during mid-day trading on Wednesday, hitting $1.84. The company’s stock had a trading volume of 135,791 shares, compared to its average volume of 469,628. VBI Vaccines has a one year low of $1.14 and a one year high of $4.17. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.61 and a quick ratio of 1.55.
In other news, major shareholder Perceptive Advisors Llc bought 14,285,714 shares of VBI Vaccines stock in a transaction that occurred on Thursday, December 13th. The stock was purchased at an average cost of $1.40 per share, with a total value of $19,999,999.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Tomer Kariv bought 1,428,571 shares of VBI Vaccines stock in a transaction that occurred on Monday, December 17th. The stock was purchased at an average cost of $1.40 per share, with a total value of $1,999,999.40. The disclosure for this purchase can be found here. 16.20% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of VBIV. Bank of Montreal Can lifted its holdings in shares of VBI Vaccines by 260.0% during the fourth quarter. Bank of Montreal Can now owns 18,000 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 13,000 shares during the period. Bank of New York Mellon Corp bought a new position in shares of VBI Vaccines during the fourth quarter valued at $51,000. Renaissance Technologies LLC bought a new position in shares of VBI Vaccines during the third quarter valued at $155,000. Dimensional Fund Advisors LP bought a new position in shares of VBI Vaccines during the second quarter valued at $223,000. Finally, Jane Street Group LLC bought a new position in shares of VBI Vaccines during the second quarter valued at $331,000. 33.14% of the stock is owned by hedge funds and other institutional investors.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Further Reading: Hedge Funds – Risk or Reward?
Get a free copy of the Zacks research report on VBI Vaccines (VBIV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com